AgingResearch.NewsJoin free

Braveheart Bio

CompanyUnited States

Braveheart Bio develops one asset, in phase 3 (BHB-1893 in hypertrophic obstructive cardiomyopathy). Mostly small molecule acting on MYH7; based in the United States.

1
Asset
Furthest stage
Phase 3
1
Trial
1
Signal

Pipeline

1

  • BHB-1893

    Cardiac myosin inhibitor that reduces myocardial hypercontractility

    Phase 3, Small molecule, MYH7, hypertrophic obstructive cardiomyopathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Deals1
  • Signals1
  • Similar companies4

Intelligence